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Abstract
In October 2016, the Advisory Committee on Immunization Practices (ACIP) updated the human 
papillomavirus (HPV) vaccination recommendation to include a 2-dose schedule for U.S. 
adolescents initiating the vaccine series before their 15th birthday. We analyzed records for >4 
million persons aged 9–17 years receiving any HPV vaccine by the end of each quarter during 
January 1, 2014–September 30, 2016 from six Immunization Information Systems Sentinel Sites, 
and reclassified HPV vaccination up-to-date coverage according to the updated recommendations. 
Compared with HPV vaccination up-to-date coverage by the 3-dose schedule only, including 
criteria for either a 2-dose or 3-dose schedule increased up-to-date coverage in 11–12, 13–14, and 
15–17 year-olds by 4.5–8.5 percentage points. The difference between 3-dose up-to-date coverage 
and 2- or 3-dose up-to-date coverage was greatest in late 2016. These data provide baseline HPV 
vaccination coverage using current ACIP recommendations.
1. Introduction
In the United States, the Advisory Committee on Immunization Practices (ACIP) has 
recommended human papillomavirus (HPV) vaccination for women since 2006 and for men 
since 2011 [1, 2]. HPV Vaccine is recommended for routine vaccination at age 11–12 years, 
and can be given starting at age 9 years. Vaccination is also recommended for women 
through age 26 years, and for men through age 21 years. HPV vaccines were first 
recommended as a 3-dose schedule, with the second dose 1–2 months after the first dose and 
the third dose 6 months after the first dose. In October 2016, ACIP recommended a 2-dose 
schedule for persons initiating the HPV vaccine series before their 15th birthday; this 
recommendation was adopted by CDC and formalized in December 2016 [3]. In the 2-dose 
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schedule, the second dose is recommended 6–12 months after the first dose1. Persons 
initiating the series on or after their 15th birthday and those with certain 
immunocompromising conditions should follow the 3-dose schedule.
Almost all HPV vaccines are delivered through primary care providers in the United States, 
in clinic-based settings [4]. Routinely recommended vaccines are available at no cost to 
vaccinees through public or private sectors [5]. National HPV vaccination coverage among 
adolescents has been increasing, with 34.9% of adolescents aged 13–17 years receiving ≥3 
doses in 2015, but still lags behind coverage for other adolescent vaccines [6]. With the 
revised ACIP recommendations, HPV vaccination up-to-date (UTD) coverage in the United 
States will be determined by including those who have completed a 2-dose schedule at the 
appropriate interval and initiation age. Our objective was to assess HPV vaccination UTD 
coverage according to either a 2-dose or 3-dose schedule among persons aged 9–17 years 
during each quarter from January 2014 through September 2016.
2. Methods
Immunization information systems (IIS) are confidential, population-based databases of 
immunization doses administered by participating vaccine providers [7]. The Centers for 
Disease Control and Prevention funded six IIS Sentinel Sites that had achieved high data 
quality standards, with ≥85% of persons aged <19 years and ≥85% of provider sites 
participating in the IIS, to evaluate vaccination coverage: Michigan, Minnesota, New York 
City, North Dakota, Oregon (six counties), and Wisconsin, constituting approximately 10% 
of the pediatric population nationwide.
We analyzed records for >4 million persons aged 9–17 years receiving any HPV vaccine by 
the end of each quarter during January 1, 2014–September 30, 2016. For each quarter, 
persons were included if they were in any of the following age groups throughout the 
quarter: 9–10, 11–12, 13–14, 15–17, or 13–17 years (period of time assessment method, 
without aging in or aging out [8]). Persons known to be deceased or not residing in the 
jurisdiction were excluded. For age groups including 15–17-year-olds, the analytic period 
was quarter 3, 2015–quarter 3, 2016 due to birth cohort limitations; persons aged 15–17 
years in quarters prior to quarter 3, 2015 may be ≥19 years old as of September 30, 2016 and 
their immunization records are not available in the dataset.
We considered an HPV vaccine dose valid if it met criteria for ACIP’s recommended age 
and interval for a 3-dose or 2-dose schedule [3]. We allowed a 4-day grace period for these 
criteria. We defined UTD status in two ways: (1) all persons aged ≥9 years who received ≥3 
valid doses of HPV vaccine per ACIP’s 3-dose schedule; or (2) all persons aged ≥9 years 
who received ≥2 valid doses of HPV vaccine per ACIP’s 2-dose schedule [3]. The U.S. 
Census estimates for total population, age group, and gender for each Sentinel Site were 
used as denominators. We used SAS® 9.4 (SAS Institute, Cary, NC) and Microsoft® Excel® 
2010 (Microsoft, Redmond, WA) for all analyses.
1Minimum interval between the first and second doses is 5 months.
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3. Results
We found 1,438,161 persons aged 9–17 years (44.3% of corresponding Census population) 
from the six Sentinel Sites who received at least one HPV vaccination. Among them, 26.0% 
received only 1 dose, 20.9% received exactly 2 doses, and 53.1% received at least 3 doses of 
HPV vaccine. Overall, 18.7% of these 1,438,161 persons initiated the HPV vaccine series 
before age 15 and received exactly 2 doses. Among them, 61.4% received the doses ≥5 
months apart, and the other 38.6% received them <5 months apart.
We reclassified HPV vaccination UTD coverage by including a 2-dose schedule (Figure 1). 
Compared with HPV vaccination UTD coverage according to a 3-dose schedule alone, 
coverage using 2-dose or 3-dose schedule criteria increased among persons of both genders 
in all age groups. The difference in UTD coverage increased over the time period of our 
analysis. The largest difference between UTD coverage using these two sets of criteria 
occurred in the most recent quarter (quarter 3, 2016) across all age groups, with percentage 
point increases among girls and boys, respectively, of 0.3 and 0.3 among 9–10-year-olds; 4.9 
and 4.5 among 11–12-year-olds; 8.5 and 8.3 among 13–14-year-olds; and 6.4 and 6.1 among 
15–17-year-olds. In adolescents aged 13–17 years, the percentage point increase in HPV 
vaccination UTD coverage from including both schedules was higher in quarter 3, 2016 (7.2; 
37.0% vs. 44.2%), compared with quarter 3, 2015 (3.7; 32.6% vs. 36.3%).
4. Discussion
This analysis established baseline HPV vaccination UTD coverage under current ACIP 
recommendations that can be used for future monitoring. It also assessed how HPV 
vaccination UTD coverage increased solely due to reclassification based on the revised 
recommendation. We found that by using 3-dose or 2-dose schedule criteria, the UTD 
coverage increased 7.2 percentage points among 13–17-year-olds in the most recent quarter, 
versus using only a 3-dose schedule criterion. We also found that the difference in UTD 
coverage by including the 2-dose schedule criterion increased over the time period of our 
analysis. Reasons for this increase are unclear. If this finding reflects intentional delay of the 
second dose rather than late administration of the second dose in a 3-dose schedule, it may 
indicate awareness of the 2-dose schedule, which was recommended by the World Health 
Organization in 2014 [9], and publicly discussed at ACIP meetings throughout 2016. Of 
note, among persons initiating HPV vaccine series before age 15 years receiving exactly two 
doses, more than a third received these doses <5 months apart, and therefore would need a 
third dose to complete the recommended series.
Our results, particularly those from the third quarter of 2015, are consistent with a previous 
analysis of data from the 2013 National Immunization Survey-Teen (NIS-Teen) [10]. That 
analysis, conducted using slightly different criteria (6-month interval between doses), found 
that if 2-dose vaccinees aged 13–17 years who received the second dose ≥6 months after the 
first dose were reclassified as having completed the HPV vaccination series, overall HPV 
vaccination UTD coverage in the United States would increase 3.9 percentage points.
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In 2015, as measured by the NIS-Teen, HPV vaccination coverage (≥3 doses) among U.S. 
adolescents aged 13–17 years (girls: 41.9%; boys: 28.1%) was below the Healthy People 
2020 goals (80% for both boys and girls aged 13–15 years) [6, 11]. HPV vaccination 
coverage in our analysis was consistent with these national estimates. ACIP recommends a 
2-dose schedule for persons starting the series before age 15 years based on immunologic 
data demonstrating that the 2-dose schedule in this age group is non-inferior to the 3-dose 
schedule. Although a 2-dose schedule decreases the total number of doses needed to 
complete the HPV vaccination series, it is not known whether the new recommendations will 
result in an increase in series initiation, since reasons reported by parents for not vaccinating 
their children with HPV vaccine have highlighted lack of knowledge, beliefs that vaccine is 
unnecessary, safety concerns, and lack of recommendation from a healthcare provider [12], 
rather than number of doses in the series. Future evaluations are warranted to assess impact 
of the 2-dose schedule recommendation on HPV vaccination coverage.
Strengths of this analysis include good quality and reliability of provider-submitted IIS data. 
Limitations include the following: first, data from six Sentinel Sites do not necessarily 
represent the entire U.S. population, although our population-based data contain records for 
>4 million persons and our HPV vaccination coverage (≥3 valid doses) was within the 2015 
NIS-Teen confidence intervals for both girls and boys; second, potentially incomplete 
vaccination histories in IIS data might underestimate vaccination coverage in the current 
analysis. However, the underestimation on HPV vaccination coverage is likely small due to 
high participation of children aged <19 years (≥85%) in the IIS Sentinel Sites, and the 
consistent HPV vaccination coverage estimates between IIS sentinel site and NIS-Teen data 
sources; the impact of any such data incompleteness on relative UTD coverage changes 
according to two sets of criteria is likely even smaller.
HPV vaccination coverage reclassification by applying the 3-dose/2-dose schedule criteria 
will result in modest increases in UTD coverage in the United States. Coverage remains 
below that of Healthy People 2020 goals and ongoing collaborative efforts involving state, 
local, and federal government resources, public health and vaccine programs, healthcare 
providers, parents, and patients are critical to sustain improvements in national HPV 
vaccination coverage and to protect U.S. adolescents against vaccine-preventable HPV-
associated diseases and cancers.
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Figure 1. 
HPV vaccination up-to-date coverage according to 3-dose and 3-dose/2-dose schedules, by 
age group and gender — six Immunization Information Systems Sentinel Sites, United 
States, Quarter 1, 2014 – Quarter 3, 2016
yo, year-olds; UTD, up-to-date
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